Empagliflozin in Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.

Also called NCT05182658

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05182658
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05182658. Randomized; triple masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin in Hypertrophic Cardiomyopathy
Acronym
EMPA-REPAIR
Condition
Hypertrophic Cardiomyopathy
Condition
Heart Failure
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
National Institute of Cardiology, Warsaw, Poland (class: other)
Collaborator
Medical University of Bialystok (class: other)
Collaborator
University of Eastern Finland (class: other)
Collaborator
Amsterdam UMC, location VUmc (class: other)

Record details

Record id
cardio:ct-nct05182658
Content hash
e707e1705d96e986a7dcb6fe5512926315cbc8c3c712bd638978cbe8aeb9c440